S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:BCPC

Balchem (BCPC) Stock Forecast, Price & News

$121.79
+1.27 (+1.05%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$118.75
$122.12
50-Day Range
$116.17
$140.54
52-Week Range
$114.79
$174.29
Volume
142,667 shs
Average Volume
118,932 shs
Market Capitalization
$3.91 billion
P/E Ratio
39.04
Dividend Yield
0.53%
Beta
0.66
30 days | 90 days | 365 days | Advanced Chart
Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter.

Balchem logo

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
Specialty Chemicals
Current Symbol
NASDAQ:BCPC
CUSIP
05766520
CIK
9326
Employees
1,317
Year Founded
1967

Sales & Book Value

Annual Sales
$799.02 million
Cash Flow
$4.59 per share
Book Value
$27.20 per share

Profitability

Net Income
$96.10 million
Pretax Margin
15.78%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,623,000
Market Cap
$3.91 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/29/2022
Today
5/23/2022
Next Earnings (Estimated)
7/29/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.70 out of 5 stars

Basic Materials Sector

38th out of 238 stocks

Chemicals & Allied Products Industry

5th out of 20 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Balchem (NASDAQ:BCPC) Frequently Asked Questions

Is Balchem a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Balchem stock.
View analyst ratings for Balchem
or view top-rated stocks.

When is Balchem's next earnings date?

Balchem is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for Balchem
.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) posted its quarterly earnings data on Friday, April, 29th. The basic materials company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.73 by $0.16. The basic materials company had revenue of $228.87 million for the quarter, compared to analyst estimates of $211 million. Balchem had a net margin of 12.07% and a trailing twelve-month return on equity of 13.02%. During the same quarter last year, the business posted $0.87 earnings per share.
View Balchem's earnings history
.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem declared an annual dividend on Friday, December 17th. Investors of record on Tuesday, December 28th will be given a dividend of $0.64 per share on Friday, January 21st. This represents a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, December 27th. This is a boost from Balchem's previous annual dividend of $0.58.
View Balchem's dividend history
.

Is Balchem a good dividend stock?

Balchem pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.53%. Balchem has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Balchem is 20.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Balchem will have a dividend payout ratio of 17.88% next year. This indicates that Balchem will be able to sustain or increase its dividend.
View Balchem's dividend history.

What price target have analysts set for BCPC?

3 Wall Street analysts have issued 12 month price objectives for Balchem's stock. Their forecasts range from $145.00 to $175.00. On average, they anticipate Balchem's share price to reach $157.33 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
View analysts' price targets for Balchem
or view top-rated stocks among Wall Street analysts.

Who are Balchem's key executives?
Balchem's management team includes the following people:
  • Mr. Theodore L. Harris, Chairman, CEO & Pres (Age 57, Pay $2.37M)
  • Mr. Carl Martin Bengtsson, CFO & Treasurer
  • Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
  • Mr. James C. Hyde, Sr. VP and GM of Human Nutrition & Health
  • Mr. Jonathan Griffin, Sr. VP and GM of Animal Nutrition & Health
What is Dino A. Rossi's approval rating as Balchem's CEO?

15 employees have rated Balchem CEO Dino A. Rossi on Glassdoor.com. Dino A. Rossi has an approval rating of 85% among Balchem's employees.

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Ecolab (ECL), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ), Lowe's Companies (LOW), Altria Group (MO), NVIDIA (NVDA), AT&T (T), Analog Devices (ADI) and Bristol-Myers Squibb (BMY).

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

Who are Balchem's major shareholders?

Balchem's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.23%), Vanguard Group Inc. (10.97%), Wasatch Advisors Inc. (4.67%), State Street Corp (3.26%), Conestoga Capital Advisors LLC (3.14%) and Dimensional Fund Advisors LP (2.03%). Company insiders that own Balchem stock include Scott C Mason and William A Backus.
View institutional ownership trends for Balchem
.

Which institutional investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wasatch Advisors Inc., Lord Abbett & CO. LLC, Santa Monica Partners LP, Healthcare of Ontario Pension Plan Trust Fund, Tributary Capital Management LLC, Eaton Vance Management, and UBS Group AG.
View insider buying and selling activity for Balchem
or view top insider-selling stocks.

Which institutional investors are buying Balchem stock?

BCPC stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Renaissance Technologies LLC, BlackRock Inc., State Street Corp, Rhumbline Advisers, Goldman Sachs Group Inc., Nordea Investment Management AB, and Congress Asset Management Co. MA.
View insider buying and selling activity for Balchem
or or view top insider-buying stocks.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $121.79.

How much money does Balchem make?

Balchem has a market capitalization of $3.91 billion and generates $799.02 million in revenue each year. The basic materials company earns $96.10 million in net income (profit) each year or $3.12 on an earnings per share basis.

How many employees does Balchem have?

Balchem employs 1,317 workers across the globe.

When was Balchem founded?

Balchem was founded in 1967.

What is Balchem's official website?

The official website for Balchem is www.balchem.com.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at (845) 326-5600, via email at [email protected], or via fax at 845-326-5717.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.